Phase II trial of suramin in patients with metastatic renal cell carcinoma

被引：24

作者：

Dreicer, R

Smith, DC

Williams, RD

See, WA

机构：

[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA

[2] Univ Iowa, Ctr Canc, Iowa City, IA USA

[3] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA

[4] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA

来源：

INVESTIGATIONAL NEW DRUGS | 1999年 / 17卷 / 02期

关键词：

carcinoma; renal cell; neoplasm metastasis; suramin;

D O I：

10.1023/A:1006331518952

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study was conducted to assess the efficacy and toxicity of suramin administered using a fixed dose schedule in patients with advanced renal cell carcinoma. Fourteen eligible patients with advanced renal cell carcinoma were enrolled and treated on a fixed dose schedule of suramin administered over 12 weeks. Suramin was administered by intravenous infusions over 1 hour. None of the 13 evaluable patients demonstrated an objective response. Only 3 patients completed the 12-week therapy course, with the majority developing progressive disease on therapy. The fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is well tolerated but has no activity in advanced renal cell carcinoma.

引用

页码：183 / 186

页数：4

共 12 条

[1]

COUILLARD DR, 1993, UROL CLIN N AM, V20, P263

[2] SURAMIN, AN ACTIVE-DRUG FOR PROSTATE-CANCER - INTERIM OBSERVATIONS IN A PHASE-I TRIAL [J].

EISENBERGER, MA ;

REYNO, LM ;

JODRELL, DI ;

SINIBALDI, VJ ;

TKACZUK, KH ;

SRIDHARA, R ;

ZUHOWSKI, EG ;

LOWITT, MH ;

JACOBS, SC ;

EGORIN, MJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (08) :611-621

[3] Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma [J].

Gleave, ME ;

Elhilali, M ;

Fradet, Y ;

Davis, I ;

Venner, P ;

Saad, F ;

Klotz, LH ;

Moore, MJ ;

Paton, V ;

Bajamonde, A .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1265-1271

[4]

Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X

[5]

LAROCCA RV, 1991, CANCER, V67, P1509, DOI 10.1002/1097-0142(19910315)67:6<1509::AID-CNCR2820670608>3.0.CO

[6]

2-F

[7] Renal-cell carcinoma [J].

Motzer, RJ ;

Bander, NH ;

Nanus, DM .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (12) :865-875

[8]

MOTZER RJ, 1992, CANCER RES, V52, P5775

[9] Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma [J].

Negrier, S ;

Escudier, B ;

Lasset, C ;

Douillard, JY ;

Savary, J ;

Chevreau, C ;

Ravaud, A ;

Mercatello, A ;

Peny, J ;

Mousseau, M ;

Philip, T ;

Tursz, T .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1272-1278

[10]

REYNO LM, 1993, P AM SOC CLIN ONCOL, V12, P135

← 1 2 →